KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Debt Ratio (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Debt Ratio for 13 consecutive years, with 0.68 as the latest value for Q3 2025.

  • On a quarterly basis, Debt Ratio fell 4.23% to 0.68 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.68, a 4.23% decrease, with the full-year FY2024 number at 0.73, down 15.64% from a year prior.
  • Debt Ratio was 0.68 for Q3 2025 at Halozyme Therapeutics, down from 0.69 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.86 in Q4 2023 to a low of 0.08 in Q3 2021.
  • A 5-year average of 0.61 and a median of 0.73 in 2024 define the central range for Debt Ratio.
  • Peak YoY movement for Debt Ratio: skyrocketed 1486.42% in 2021, then dropped 15.64% in 2024.
  • Halozyme Therapeutics' Debt Ratio stood at 0.79 in 2021, then rose by 3.03% to 0.82 in 2022, then increased by 5.76% to 0.86 in 2023, then decreased by 15.64% to 0.73 in 2024, then dropped by 6.8% to 0.68 in 2025.
  • Per Business Quant, the three most recent readings for HALO's Debt Ratio are 0.68 (Q3 2025), 0.69 (Q1 2025), and 0.73 (Q4 2024).